{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:55:50Z","timestamp":1792580150749,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>There is an unmet need in the treatment of perianal fistulising Crohn\u2019s disease [PFCD]. This study evaluated the efficacy and safety of the Janus kinase 1 preferential inhibitor, filgotinib, for the treatment of PFCD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This phase 2, double-blind, multicentre trial enrolled adults with PFCD and prior treatment failure. Participants were randomised [2:2:1] to receive filgotinib 200 mg, filgotinib 100 mg, or placebo, once daily orally for up to 24 weeks. The primary endpoint was combined fistula response (reduction from baseline of at least one draining external opening determined by physical assessment, and no fluid collections\u2005&amp;gt;1 cm on pelvic magnetic resonance imaging [MRI]) at Week 24.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between April 2017 and July 2020, 106 individuals were screened and 57 were randomised. Discontinuations were lowest in the filgotinib 200 mg group (3\/17 [17.6%] versus 13\/25 [52.0%] for filgotinib 100 mg and 9\/15 [60.0%] for placebo). The proportion of participants who achieved a combined fistula response at Week 24 was 47.1% (8\/17; 90% confidence interval [CI] 26.0, 68.9%) in the filgotinib 200 mg group, 29.2% [7\/24; 90% CI 14.6, 47.9%] in the filgotinib 100 mg group, and 25.0% [3\/12; 90% CI 7.2, 52.7%] in the placebo group. Serious adverse events occurred more frequently with filgotinib 200 mg (5\/17 [29.4%]) than with placebo (1\/15 [6.7%]). There were no treatment-related serious adverse events or deaths.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Filgotinib 200 mg was associated with numerical reductions in the number of draining perianal fistulas based on combined clinical and MRI findings compared with placebo, and was generally well tolerated [NCT03077412].<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae003","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T08:01:50Z","timestamp":1708156910000},"page":"864-874","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn\u2019s Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-091X","authenticated-orcid":false,"given":"Walter","family":"Reinisch","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[{"name":"Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-4046","authenticated-orcid":false,"given":"Geert R","family":"D\u2019Haens","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rimola","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Department of Radiology, Hospital Clinic of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Masior","sequence":"additional","affiliation":[{"name":"Galapagos NV , Mechelen , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"McKevitt","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehan","family":"Ren","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Serone","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina B","family":"Gecse","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"2024060402062081400_CIT0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2024060402062081400_CIT0002","doi-asserted-by":"crossref","first-page":"13205","DOI":"10.3748\/wjg.v20.i37.13205","article-title":"Treatment of peri-anal fistula in Crohn\u2019s disease","volume":"20","author":"Sica","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2024060402062081400_CIT0003","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.gastro.2003.08.025","article-title":"AGA technical review on perianal Crohn\u2019s disease","volume":"125","author":"Sandborn","year":"2003","journal-title":"Gastroenterology"},{"key":"2024060402062081400_CIT0004","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/17474124.2019.1608818","article-title":"Recent advances in the management of perianal fistulising Crohn\u2019s disease: lessons for the clinic","volume":"13","author":"Lopez","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2024060402062081400_CIT0005","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"2024060402062081400_CIT0006","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulising Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"2024060402062081400_CIT0007","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2468-1253(22)00088-7","article-title":"Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn\u2019s disease [PISA-II]: a patient preference randomised trial","volume":"7","author":"Meima-van Praag","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024060402062081400_CIT0008","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","article-title":"Expanded allogeneic adipose-derived mesenchymal stem cells [Cx601] for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial","volume":"388","author":"Pan\u00e9s","year":"2016","journal-title":"Lancet"},{"key":"2024060402062081400_CIT0009","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2017.12.020","article-title":"Long-term efficacy and safety of stem cell therapy [Cx601] for complex perianal fistulas in patients with Crohn\u2019s disease","volume":"154","author":"Pan\u00e9s","year":"2018","journal-title":"Gastroenterology"},{"key":"2024060402062081400_CIT0010","volume-title":"Summary of Product Characteristics, Alofisel","author":"Takeda UK","year":"2023"},{"key":"2024060402062081400_CIT0011","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic mechanisms of JAK inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"2024060402062081400_CIT0012","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/rheumatology\/kez002","article-title":"Clinical significance of Janus kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2018","journal-title":"Rheumatology"},{"key":"2024060402062081400_CIT0013","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","article-title":"Jak selectivity for inflammatory bowel disease treatment: does it clinically matter","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"2024060402062081400_CIT0014","volume-title":"Galapagos nv. Summary of Product Characteristics, Jyseleca","year":"2022"},{"key":"2024060402062081400_CIT0015","year":"2022"},{"key":"2024060402062081400_CIT0016","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib [the FITZROY study]: results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"2024060402062081400_CIT0017","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0016-5085(03)00877-1","article-title":"Tacrolimus for the treatment of fistulas in patients with Crohn\u2019s disease: a randomised, placebo-controlled trial","volume":"125","author":"Sandborn","year":"2003","journal-title":"Gastroenterology"},{"key":"2024060402062081400_CIT0018","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2036.2004.01917.x","article-title":"The medical treatment of Crohn\u2019s perianal fistulas","volume":"19","author":"Schwartz","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2024060402062081400_CIT0019","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1007\/s10620-008-0545-y","article-title":"Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulising Crohn\u2019s disease","volume":"54","author":"Tougeron","year":"2009","journal-title":"Dig Dis Sci"},{"key":"2024060402062081400_CIT0020","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/j.cgh.2020.12.024","article-title":"Natural history of perianal Crohn\u2019s disease: long-term follow-up of a population-based cohort","volume":"20","author":"Brochard","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae003\/56720748\/jjae003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/6\/864\/58069541\/jjae003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/6\/864\/58069541\/jjae003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T02:06:56Z","timestamp":1717466816000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/6\/864\/7609165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,2,16]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae003","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,2,16]]}}}